E. Winningham Rick's most recent trade in Jazz Pharmaceuticals plc was a trade of 3,415 Ordinary Shares done at an average price of $138.1 . Disclosure was reported to the exchange on May 22, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Jazz Pharma PLC | Rick E. Winningham | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 138.08 per share. | 22 May 2026 | 3,415 | 12,308 (0%) | 0% | 138.1 | 471,543 | Ordinary Shares |
| Jazz Pharma PLC | Rick E. Winningham | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 May 2026 | 3,415 | 0 | - | - | Non-Qualified Stock Option (right to buy) | |
| Jazz Pharma PLC | Rick E. Winningham | Director | Sale of securities on an exchange or to another person at price $ 241.57 per share. | 22 May 2026 | 2,741 | 9,567 (0%) | 0% | 241.6 | 662,143 | Ordinary Shares |
| Theravance Biopharma Inc | Rick E. Winningham | Director, CHIEF EXECUTIVE OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 16.55 per share. | 20 May 2026 | 20,038 | 1,631,056 (2%) | 0% | 16.6 | 331,629 | Ordinary Shares |
| Theravance Biopharma Inc | Rick E. Winningham | Director, CHIEF EXECUTIVE OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2026 | 75,000 | 1,651,094 (2%) | 0% | 0 | Ordinary Shares | |
| Theravance Biopharma Inc | Rick E. Winningham | Director, CHIEF EXECUTIVE OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 17.90 per share. | 19 Nov 2025 | 56,817 | 1,651,069 (2%) | 0% | 17.9 | 1,017,024 | Ordinary Shares |
| Theravance Biopharma Inc | Rick E. Winningham | Director, CHIEF EXECUTIVE OFFICER | Gift of securities by or to the insider at price $ 0.00 per share. | 19 Nov 2025 | 9,900 | 1,707,886 (2%) | 0% | 0 | Ordinary Shares | |
| Theravance Biopharma Inc | Rick E. Winningham | Director, CHIEF EXECUTIVE OFFICER | Gift of securities by or to the insider at price $ 0.00 per share. | 19 Nov 2025 | 9,900 | 23,400 (0%) | 0% | 0 | Ordinary Shares | |
| Jazz Pharma PLC | Rick E. Winningham | Director | Sale of securities on an exchange or to another person at price $ 180.86 per share. | 18 Nov 2025 | 5,500 | 8,893 (0%) | 0% | 180.9 | 994,728 | Ordinary Shares |
| Theravance Biopharma Inc | Rick E. Winningham | Director, CHIEF EXECUTIVE OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 13.39 per share. | 20 Aug 2025 | 15,394 | 1,717,786 (2%) | 0% | 13.4 | 206,126 | Ordinary Shares |
| Jazz Pharma PLC | Rick E. Winningham | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Aug 2025 | 3,507 | 16,198 (0%) | 0% | 0 | Ordinary Shares | |
| Jazz Pharma PLC | Rick E. Winningham | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 111.25 per share. | 07 Aug 2025 | 1,805 | 14,393 (0%) | 0% | 111.3 | 200,811 | Ordinary Shares |
| Theravance Biopharma Inc | Rick E. Winningham | Director, CHIEF EXECUTIVE OFFICER | Gift of securities by or to the insider at price $ 0.00 per share. | 23 Jun 2025 | 20,000 | 1,733,180 (2%) | 0% | 0 | Ordinary Shares | |
| Theravance Biopharma Inc | Rick E. Winningham | Director, CHIEF EXECUTIVE OFFICER | Gift of securities by or to the insider at price $ 0.00 per share. | 13 Jun 2025 | 9,600 | 1,753,180 (2%) | 0% | 0 | Ordinary Shares | |
| Theravance Biopharma Inc | Rick E. Winningham | Director, CHIEF EXECUTIVE OFFICER | Gift of securities by or to the insider at price $ 0.00 per share. | 13 Jun 2025 | 9,600 | 13,500 (0%) | 0% | 0 | Ordinary Shares | |
| Theravance Biopharma Inc | Rick E. Winningham | Director, CHIEF EXECUTIVE OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 9.45 per share. | 20 May 2025 | 15,364 | 1,762,780 (2%) | 0% | 9.5 | 145,190 | Ordinary Shares |
| Theravance Biopharma Inc | Rick E. Winningham | Director, CHIEF EXECUTIVE OFFICER | Grant, award, or other acquisition of securities at price $ 9.35 per share. | 28 Feb 2025 | 2,178 | 1,778,144 (2%) | 0% | 9.3 | 20,364 | Ordinary Shares |
| Theravance Biopharma Inc | Rick E. Winningham | Director, CHIEF EXECUTIVE OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 9.66 per share. | 20 Feb 2025 | 35,129 | 1,775,966 (2%) | 0% | 9.7 | 339,346 | Ordinary Shares |
| Theravance Biopharma Inc | Rick E. Winningham | Director, CHIEF EXECUTIVE OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 9.97 per share. | 20 Nov 2024 | 15,997 | 1,811,095 (2%) | 0% | 10.0 | 159,490 | Ordinary Shares |
| Theravance Biopharma Inc | Rick E. Winningham | Director, CHIEF EXECUTIVE OFFICER | Grant, award, or other acquisition of securities at price $ 9.57 per share. | 14 Nov 2024 | 3,193 | 1,827,092 (2%) | 0% | 9.6 | 30,557 | Ordinary Shares |
| Theravance Biopharma Inc | Rick E. Winningham | Director, CHIEF EXECUTIVE OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 8.22 per share. | 20 Aug 2024 | 15,997 | 1,823,899 (2%) | 0% | 8.2 | 131,495 | Ordinary Shares |
| Theravance Biopharma Inc | Rick E. Winningham | Director, CHIEF EXECUTIVE OFFICER | Grant, award, or other acquisition of securities at price $ 7.83 per share. | 07 Aug 2024 | 3,252 | 1,839,896 (2%) | 0% | 7.8 | 25,463 | Ordinary Shares |
| Jazz Pharma PLC | Rick E. Winningham | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Aug 2024 | 3,731 | 14,175 (0%) | 0% | 0 | Ordinary Shares | |
| Jazz Pharma PLC | Rick E. Winningham | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 111.35 per share. | 02 Aug 2024 | 1,484 | 12,691 (0%) | 0% | 111.3 | 165,243 | Ordinary Shares |
| Theravance Biopharma Inc | Rick E. Winningham | Director, CHIEF EXECUTIVE OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 9.10 per share. | 20 May 2024 | 15,997 | 1,836,644 (2%) | 0% | 9.1 | 145,573 | Ordinary Shares |
| Theravance Biopharma Inc | Rick E. Winningham | Director, CHIEF EXECUTIVE OFFICER | Grant, award, or other acquisition of securities at price $ 9.85 per share. | 15 May 2024 | 2,068 | 1,852,641 (2%) | 0% | 9.9 | 20,370 | Ordinary Shares |
| Theravance Biopharma Inc | Rick E. Winningham | Director, CHIEF EXECUTIVE OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Apr 2024 | 300,000 | 1,850,573 (2%) | 0% | 0 | Ordinary Shares | |
| Theravance Biopharma Inc | Rick E. Winningham | Director, CHIEF EXECUTIVE OFFICER | Gift of securities by or to the insider at price $ 0.00 per share. | 15 Mar 2024 | 7,000 | 1,554,473 (2%) | 0% | 0 | Ordinary Shares | |
| Theravance Biopharma Inc | Rick E. Winningham | Director, CHIEF EXECUTIVE OFFICER | Gift of securities by or to the insider at price $ 0.00 per share. | 15 Mar 2024 | 3,900 | 1,550,573 (2%) | 0% | 0 | Ordinary Shares | |
| Theravance Biopharma Inc | Rick E. Winningham | Director, CHIEF EXECUTIVE OFFICER | Gift of securities by or to the insider at price $ 0.00 per share. | 15 Mar 2024 | 3,900 | 3,900 (0%) | 0% | 0 | Ordinary Shares | |
| Theravance Biopharma Inc | Rick E. Winningham | Director, CHIEF EXECUTIVE OFFICER | Grant, award, or other acquisition of securities at price $ 8.64 per share. | 15 Mar 2024 | 2,704 | 1,561,473 (2%) | 0% | 8.6 | 23,363 | Ordinary Shares |
| Theravance Biopharma Inc | E. Winningham Rick | Director, CHIEF EXECUTIVE OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 8.92 per share. | 20 Feb 2024 | 37,196 | 1,558,769 (2%) | 0% | 8.9 | 331,788 | Ordinary Shares |
| Theravance Biopharma Inc | Rick E. Winningham | Director, CHIEF EXECUTIVE OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 9.70 per share. | 20 Aug 2023 | 15,804 | 1,611,769 (2%) | 0% | 9.7 | 153,299 | Ordinary Shares |
| Jazz Pharma PLC | Rick E. Winningham | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Aug 2023 | 3,075 | 11,685 (0%) | 0% | 0 | Ordinary Shares | |
| Jazz Pharma PLC | Rick E. Winningham | Director | Sale of securities on an exchange or to another person at price $ 138.16 per share. | 11 Aug 2023 | 1,241 | 10,444 (0%) | 0% | 138.2 | 171,455 | Ordinary Shares |
| Theravance Biopharma Inc | Rick E. Winningham | Director, CHIEF EXECUTIVE OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 11.21 per share. | 20 May 2023 | 15,804 | 1,627,573 (2%) | 0% | 11.2 | 177,163 | Ordinary Shares |
| Theravance Biopharma Inc | Rick E. Winningham | Director, CHIEF EXECUTIVE OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2023 | 330,000 | 1,643,377 (2%) | 0% | 0 | Ordinary Shares | |
| Theravance Biopharma Inc | Rick E. Winningham | Director, CHIEF EXECUTIVE OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 10.44 per share. | 20 Feb 2023 | 37,420 | 1,313,377 (2%) | 0% | 10.4 | 390,665 | Ordinary Shares |
| Theravance Biopharma Inc | Rick E. Winningham | Director, CHIEF EXECUTIVE OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 10.85 per share. | 20 Nov 2022 | 15,804 | 1,409,797 (2%) | 0% | 10.8 | 171,473 | Ordinary Shares |
| Theravance Biopharma Inc | Rick E. Winningham | Director, CHIEF EXECUTIVE OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 9.34 per share. | 19 Aug 2022 | 15,804 | 1,424,784 (2%) | 0% | 9.3 | 147,609 | Ordinary Shares |
| Jazz Pharma PLC | Rick E. Winningham | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Aug 2022 | 2,561 | 9,699 (0%) | 0% | 0 | Ordinary Shares | |
| Jazz Pharma PLC | Rick E. Winningham | Director | Sale of securities on an exchange or to another person at price $ 152.32 per share. | 05 Aug 2022 | 1,089 | 8,610 (0%) | 0% | 152.3 | 165,879 | Ordinary Shares |
| Theravance Biopharma Inc | Rick E. Winningham | Director, CHIEF EXECUTIVE OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 8.74 per share. | 20 May 2022 | 11,025 | 1,440,588 (2%) | 0% | 8.7 | 96,359 | Ordinary Shares |
| Theravance Biopharma Inc | Rick E. Winningham | Director, CHIEF EXECUTIVE OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Feb 2022 | 515,000 | 515,000 | - | - | Share Option (Right to Buy) | |
| Theravance Biopharma Inc | Rick E. Winningham | Director, CHIEF EXECUTIVE OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Feb 2022 | 170,000 | 1,449,300 (2%) | 0% | 0 | Ordinary Shares | |
| Theravance Biopharma Inc | Rick E. Winningham | Director, CHIEF EXECUTIVE OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 9.61 per share. | 18 Feb 2022 | 22,710 | 1,279,300 (2%) | 0% | 9.6 | 218,243 | Ordinary Shares |
| Theravance Biopharma Inc | Rick E. Winningham | Director, CHIEF EXECUTIVE OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 8.36 per share. | 19 Nov 2021 | 11,404 | 1,302,010 (2%) | 0% | 8.4 | 95,337 | Ordinary Shares |
| Theravance Biopharma Inc | Rick E. Winningham | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 14.05 per share. | 20 Aug 2021 | 11,404 | 1,313,414 (2%) | 0% | 14.0 | 160,226 | Ordinary Shares |
| Jazz Pharma PLC | Rick E. Winningham | Director | Sale of securities on an exchange or to another person at price $ 147.96 per share. | 06 Aug 2021 | 1,306 | 7,138 (0%) | 0% | 148.0 | 193,236 | Ordinary Shares |
| Jazz Pharma PLC | Rick E. Winningham | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Jul 2021 | 2,246 | 8,444 (0%) | 0% | 0 | Ordinary Shares |